Silence Therapeutics plc Foreign Currency Transaction Gain (Loss), before Tax
Silence Therapeutics plc (SLN) reported Foreign Currency Transaction Gain (Loss), before Tax of $151.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-10
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $151.00K.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$482.00K.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$19.00K, a 100.16% decline year-over-year.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $1.93M.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for fiscal 2025 was -$8.47M, a 1410.68% decline from fiscal 2024.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for fiscal 2024 was $646.00K.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for fiscal 2023 was -$2.64M, a 304.10% decline from fiscal 2022.
- Silence Therapeutics plc foreign currency transaction gain (loss), before tax for fiscal 2022 was $1.29M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.00K 10-Q · filed 2026-08-10 | -$331.00K 10-Q · filed 2026-08-10 | -$350.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$482.00K 10-Q · filed 2026-05-07 | -$501.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.43M derived: sum of 3 quarters · filed 2026-05-07 | -$5.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.92M derived: sum of 2 quarters · filed 2026-03-05 | -$4.70M derived: sum of 3 quarters · filed 2026-08-10 | -$8.47M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.93M 10-Q · filed 2025-11-06 | -$4.68M derived: sum of 2 quarters · filed 2026-08-10 | -$8.45M 10-Q · filed 2025-11-06 | $3.46M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$6.61M 10-Q · filed 2026-08-10 | -$10.38M 10-Q · filed 2026-08-10 | $1.53M derived: sum of 3 quarters · filed 2026-08-10 | -$9.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$3.77M 10-Q · filed 2026-05-07 | $8.14M derived: sum of 2 quarters · filed 2026-05-07 | -$3.25M derived: sum of 3 quarters · filed 2026-05-07 | -$3.48M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $516.00K derived: sum of 2 quarters · filed 2026-03-05 | $294.00K derived: sum of 3 quarters · filed 2026-03-05 | $646.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$11.40M 10-Q · filed 2025-11-06 | -$11.62M derived: sum of 2 quarters · filed 2025-11-06 | -$11.27M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$222.00K 10-Q · filed 2025-08-07 | $129.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $351.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$2.64M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $1.29M 10-K · filed 2025-02-27 |